Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of stage IV or incurable
             non-squamous non-small cell lung cancer with a documented ROS1 rearrangement (cohort
             1) or MET-activating mutation (exon 14) (cohort 2) or MET-amplification (cohort 3)
             tested in either plasma or tissue, as applicable

          -  18 years of age or older.

          -  Measurable disease as per RECIST v1.1.

          -  Adequate hematologic and organ function within 7 days of the proposed start date of
             treatment and adequate cardiac function within 28 days of the proposed start date of
             treatment

          -  Life expectancy >12 weeks.

          -  Have the ability to understand and the willingness to sign a written informed consent
             document

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  No contraindication to Crizotinib therapy

          -  Able to swallow and retain oral medication and does not have any clinically
             significant gastrointestinal abnormalities that may alter absorption such as
             malabsorption syndrome or major resection of the stomach or bowels.

          -  No pregnant

          -  Agree to use methods (as agreed upon by the study doctor and participant) before the
             study and for at least 120 days after the last dose of study drug to prevent pregnancy

        Exclusion Criteria:

          -  Symptomatic untreated brain metastases.

          -  Had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents
             (e.g. targeted therapy or antibodies) within 4 weeks or radiotherapy within 2 weeks
             prior to the proposed first dose of study treatment.

          -  Adverse events attributed to prior anti-cancer therapy > Grade 1 if clinically
             relevant.

          -  Receiving medications or substances known to be strong inhibitors or inducers of
             CYP3A4.

          -  Any known intolerance to agents structurally similar to crizotinib.

          -  Congenital long QT syndrome or persistent corrected QT interval by Fredericia formula
             (QTcF) ≥ 500 msec.

          -  Any other condition that would, in the Investigator's judgment, contraindicate the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures, e.g., infection/inflammation, intestinal obstruction,
             unable to swallow medication, social/ psychological issues